Merck & Co. Inc. (NYSE:MRK) on Wednesday announced a strategic collaboration with Mayo Clinic to leverage artificial intelligence (AI) and advanced analytics in drug discovery.

This partnership aims to enhance the development of tailored therapies, adding pressure as broader markets edged lower.

Merck on Wednesday said Mayo Clinic is the world’s top-ranked hospital system.

Under this agreement, Merck will utilize Mayo Clinic’s extensive multimodal data, including laboratory results and clinical insights, to validate AI models and improve drug development strategies.

This collaboration marks Mayo Clinic’s first strategic partnership of this scale with a global biopharmaceutical company, reflecting a significant step in integrating clinical data with AI capabilities.

The partnership will initially focus on high-need therapeutic areas, where advanced analytics can drive progress in developing more effective therapies, including Inflammatory bowel disease, atopic dermatitis, and multiple sclerosis.

Technical Analysis

Merck is currently trading 6.1% above its 20-day simple moving average (SMA) and 11.4% above its 100-day SMA, demonstrating longer-term strength. Shares have increased 45.96% over the past ...